causal
Mandated clinical trials favor incumbents and small innovations
The FDA's mandate that only randomized, double-blind clinical trials count as knowledge of drug effectiveness is so expensive that only big incumbents can pass the screen, and since incumbents are less likely to make breakthroughs, this skews innovation toward small, unimportant advances rather than transformative ones.
causalpending
Speaker
Arthur DiamondEvidence Quote
“if the only people who can make it through the screen of the FDA's methodology are the big incumbents, that's going to result in a lot of small, unimportant-in-general, innovations.”
Created: 6/13/2026, 12:15:58 AM
Your notes
Loading notes...